Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 21, 2025
DataAggregated Company Financials
Companies565
- 7D5.0%
- 3M-8.4%
- 1Y-11.6%
- YTD-3.7%
In the last week, the Biotech industry is up 5.0%, with Gilead Sciences up 7.6%. In the past year, the industry is down 12%. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 21 May 2025 | US$909.2b | US$155.9b | -US$24,386,632,960.38 | 15.9x | -37.3x | 5.8x |
| Fri, 18 Apr 2025 | US$749.3b | US$119.2b | -US$36,618,281,612.03 | 19.4x | -20.5x | 6.3x |
| Sun, 16 Mar 2025 | US$838.4b | US$118.4b | -US$37,606,321,265.93 | 18.5x | -22.3x | 7.1x |
| Tue, 11 Feb 2025 | US$841.4b | US$117.4b | -US$36,256,461,776.76 | 17.7x | -23.2x | 7.2x |
| Thu, 09 Jan 2025 | US$972.7b | US$149.4b | -US$26,292,741,879.89 | 17.2x | -37x | 6.5x |
| Sat, 07 Dec 2024 | US$1.0t | US$150.0b | -US$26,481,489,967.01 | 17.9x | -38.7x | 6.8x |
| Mon, 04 Nov 2024 | US$1.1t | US$147.4b | -US$30,522,373,860.52 | 17.6x | -35x | 7.2x |
| Wed, 02 Oct 2024 | US$899.5b | US$113.2b | -US$35,974,034,598.12 | 21.4x | -25x | 7.9x |
| Fri, 30 Aug 2024 | US$906.0b | US$113.1b | -US$35,694,070,050.33 | 23.9x | -25.4x | 8x |
| Sun, 28 Jul 2024 | US$1.2t | US$164.9b | -US$28,965,808,648.76 | 26.4x | -43x | 7.5x |
| Tue, 25 Jun 2024 | US$1.2t | US$164.4b | -US$27,944,795,069.74 | 28.1x | -41.4x | 7x |
| Thu, 23 May 2024 | US$1.1t | US$164.6b | -US$26,731,616,038.85 | 24.6x | -42.6x | 6.9x |
| Sat, 20 Apr 2024 | US$1.1t | US$164.2b | -US$23,337,120,518.73 | 20.4x | -45.9x | 6.5x |
| Mon, 18 Mar 2024 | US$1.2t | US$167.4b | -US$22,071,849,383.64 | 13.9x | -53.2x | 7x |
| Wed, 14 Feb 2024 | US$1.1t | US$168.9b | -US$20,817,013,760.70 | 18x | -54.6x | 6.7x |
| Fri, 12 Jan 2024 | US$1.4t | US$204.8b | -US$22,495,274,678.00 | 19.2x | -64.1x | 7x |
| Sun, 10 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.3x | 6.3x |
| Tue, 07 Nov 2023 | US$1.2t | US$203.9b | -US$22,185,418,652.00 | 18.9x | -56x | 6.1x |
| Thu, 05 Oct 2023 | US$1.2t | US$207.3b | -US$13,076,809,948.00 | 16.7x | -94.9x | 6x |
| Sat, 02 Sep 2023 | US$1.3t | US$207.6b | -US$12,424,624,459.00 | 18.4x | -104.2x | 6.2x |
| Mon, 31 Jul 2023 | US$1.2t | US$186.0b | -US$15,168,211,533.00 | 14.7x | -76.1x | 6.2x |
| Wed, 28 Jun 2023 | US$1.1t | US$186.3b | -US$16,125,527,732.00 | 13.5x | -69.1x | 6x |
| Fri, 26 May 2023 | US$1.1t | US$185.9b | -US$15,950,003,280.00 | 11.5x | -71.8x | 6.2x |
| Sun, 23 Apr 2023 | US$1.2t | US$198.4b | -US$3,214,788,122.00 | 13.9x | -370.1x | 6x |
| Tue, 21 Mar 2023 | US$1.1t | US$199.3b | -US$3,748,498,766.00 | 12.7x | -301.2x | 5.7x |
| Thu, 16 Feb 2023 | US$1.2t | US$202.5b | US$17.8m | 16.3x | 64811.8x | 5.7x |
| Sat, 14 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.8x | 5.8x |
| Mon, 12 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.6x | 811.7x | 5.6x |
| Wed, 09 Nov 2022 | US$1.1t | US$204.5b | US$3.9b | 14.4x | 280.2x | 5.3x |
| Fri, 07 Oct 2022 | US$1.1t | US$206.2b | US$5.5b | 15.1x | 193.6x | 5.1x |
| Sun, 04 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 167.9x | 5x |
| Tue, 02 Aug 2022 | US$1.0t | US$212.2b | US$11.4b | 15.4x | 90.7x | 4.9x |
| Thu, 30 Jun 2022 | US$1.0t | US$212.2b | US$11.0b | 15.7x | 94.5x | 4.9x |
| Sat, 28 May 2022 | US$1.0t | US$212.7b | US$11.1b | 16.1x | 92.8x | 4.8x |
Price to Earnings Ratio
92.8x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.50% | |
| Healthcare | 2.31% | |
| Biotech | 4.98% | |
| Biotech | 4.98% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$109.11 | 7.6% +US$9.6b | 62.1% | PE22.8x | |
| REGN Regeneron Pharmaceuticals | US$614.79 | 7.1% +US$4.3b | -38.1% | PE14.4x | |
| VRTX Vertex Pharmaceuticals | US$447.18 | 3.5% +US$3.9b | 1.2% | PS10.3x | |
| ALNY Alnylam Pharmaceuticals | US$291.68 | 9.3% +US$3.2b | 94.9% | PS16.2x | |
| AMGN Amgen | US$275.01 | 1.7% +US$2.5b | -12.7% | PE24.9x |
